A prospective trial of midwest breast cancer patients: A p53 gene mutation is the most important predictor of adverse outcome
✍ Scribed by Hagen Blaszyk; Arndt Hartmann; Julie M. Cunningham; Daniel Schaid; Lester E. Wold; John S. Kovach; Steve S. Sommer
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- French
- Weight
- 106 KB
- Volume
- 89
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p ؍ 0.0032) and death (p ؍ 0.0001), and was associated with poor response to both adjuvant (p ؍ 0.0001) and palliative (p ؍ 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients.